inactivated poliovirus vaccine (IPV)
GPTKB entity
Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:poliomyelitis
|
| gptkbp:age |
2 months
|
| gptkbp:availability |
widely available
|
| gptkbp:average_temperature |
2-8 ° C
|
| gptkbp:avionics |
contains inactivated virus
|
| gptkbp:can_be_used_with |
gptkb:oral_poliovirus_vaccine_(OPV)
|
| gptkbp:clinical_trial |
extensively tested
|
| gptkbp:contraindication |
severe allergic reaction to vaccine components
|
| gptkbp:defense |
recommended for all children
|
| gptkbp:developed_by |
gptkb:Jonas_Salk
|
| gptkbp:dosage_form |
4-6 years
3 doses |
| gptkbp:first_introduced |
gptkb:1955
|
| gptkbp:genetic_diversity |
all three serotypes
|
| https://www.w3.org/2000/01/rdf-schema#label |
inactivated poliovirus vaccine (IPV)
|
| gptkbp:is_effective_against |
95% or higher
|
| gptkbp:is_vulnerable_to |
vaccine hesitancy
long-lasting immunity approved by FDA ongoing research for improvements educational programs for parents improves public health outcomes administered by healthcare professionals subunit vaccine increased public awareness campaigns liquid suspension high in developed countries collaboration with NG Os significantly reduced polio cases monitored for safety and efficacy 4 doses recommended in some countries cost-effective in preventing polio distributed through public health systems important for global health initiatives induces strong immune response part of global vaccination campaigns updated regularly based on research |
| gptkbp:manager |
intramuscular injection
|
| gptkbp:part_of |
routine immunization schedule
|
| gptkbp:produced_by |
various pharmaceutical companies
|
| gptkbp:regulates |
regulated by health authorities
|
| gptkbp:safety_features |
generally safe
|
| gptkbp:side_effect |
injection site reactions
mild fever |
| gptkbp:succeeded_by |
contributed to polio eradication in many regions
|
| gptkbp:suitable_for |
gptkb:Centers_for_Disease_Control_and_Prevention_(CDC)
gptkb:World_Health_Organization_(WHO) immunocompromised individuals |
| gptkbp:targets |
gptkb:poliomyelitis
|
| gptkbp:type |
inactivated vaccine
|
| gptkbp:used_in |
polio eradication efforts
|
| gptkbp:variant |
new formulations under development
|
| gptkbp:volunteer_opportunities |
community outreach programs
|